Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials-Reference-Cited by-同舟云学术

Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials

Published:2017-10 Issue:5 Volume:44 Page:358-371
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Poorthuis Michiel H.F.,Vernooij Robin W.M.,van Moorselaar R. Jeroen. A.,de Reijke Theo M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference62 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

4. First-line non-cytotoxic therapy in chemotherapy-naive patient with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials;Poorthuis;BJU Int,2017

5. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement;Moher;PLoS Med,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade;Anti-Cancer Drugs;2022-11-15

2. Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review;Cancers;2022-08-03

3. The histidine phosphatase LHPP: an emerging player in cancer;Cell Cycle;2022-03-03

4. The lncRNA NEAT1/miRNA-766-5p/E2F3 Regulatory Axis Promotes Prostate Cancer Progression;Journal of Oncology;2022-02-21

5. Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates;Asia-Pacific Journal of Clinical Oncology;2021-04